GloPID-R report on Chikungunya, O’nyong-nyong and Mayaro virus, part I: biological diagnostics

Pezzi L1,2, Reusken CB3,4, Weaver SC5, Drexler JF6,7, Busch M8, LaBeaud AD9, Diamond MS10, Vasilakis N11, Drebot MA12, Siqueira AM13, Ribeiro GS14, Kohl A15, Lecuit M16, Ng LFP17, Gallian P18, de Lamballerie X1 on behalf of GloPID-R Chikungunya, O’nyong-nyong and Mayaro virus Working Group\*

\* Collaborators:

Boyer S19, Brasil P13, Diallo M20, Failloux AB21, Jaenisch T22, Lourenço-de-Oliveira R23, Neyts J24, Rios M25, Rodriguez-Morales AJ26, Rosa-Freitas MG23, Sall A20, Simmons G27, Simon F28, Vega Rua A29

1 Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.

2 EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.

3 Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

4 Department Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.

5 Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA.

6 Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany.

7 German Centre for Infection Research (DZIF), Germany.

8 Blood Systems Research Institute, San Francisco, and Department of Laboratory Medicine, University of California, San Francisco, USA.

9 Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, USA.

10 Departments of Medicine, Molecular Microbiology, Pathology and Immunology, and The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA.

11 Department of Pathology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, USA.

12 Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

13 Instituto Nacional de Infectologia Evandro Chagas - Oswaldo Cruz Foundation, Rio de Janeiro, Brasil.

14 Gonçalo Moniz Institute, Oswaldo Cruz Foundation, and Federal University of Bahia, Salvador, Brazil.

15 MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.

16 Institut Pasteur,Biology of Infection Unit; Inserm U1117; Paris Descartes University, Departement of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, APHP, IHU Imagine, Paris, France.

17 Singapore Immunology Network, Agency for Science, Technology and Research (A\*STAR), Singapore.

18 Établissement Français du Sang Alpes Méditerranée, Marseille, France.

19 Medical Entomology Platform, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

20 Unité d'Entomologie Médicale, Institut Pasteur de Dakar, Dakar, Senegal.

21 Department of Virology, Institut Pasteur, Arboviruses and Insect Vectors Unit, Paris, France.

22 Section Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.

23 Instituto Oswaldo Cruz-Fiocruz, Laboratório de Mosquitos Transmissores de Hematozoários, Rio de Janeiro, Brasil.

24 KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.

25 Division of Emerging and Transfusion Transmitted Diseases, Laboratory of Emerging Pathogens, Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA.

26 Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia.

27 Blood Systems Research Institute, San Francisco, USA, and Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, USA.

28 Laveran Military Teaching Hospital, Marseille, France.

29 Laboratory of Vector Control Research, Environment and Health Unit, Institut Pasteur de la Guadeloupe, Guadeloupe, France.

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness, <https://www.glopid-r.org/>) Chikungunya (CHIKV), O’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group is investigating the natural history, epidemiology and medical management of infection by these viruses, to identify knowledge gaps and to propose recommendations for direct future investigations and rectification measures. This first report is dedicated to diagnostic aspects of CHIKV, ONNV and MAYV.

|  |  |  |  |
| --- | --- | --- | --- |
| Kit | Company | Method | Published evaluation |
| Human Anti-CHIKV IgG ELISA Kit | Abcam | IgG ELISA | NA |
| Chikungunya Virus IgG capture ELISA Kit | CD Creative Diagnostics | IgG ELISA | NA |
| Human Chikungunya IgG ELISA Kit | NA |
| [CHIKUNGUNYA IgG](http://www.diesse.it/en/Products/dettaglio:272/Chorus-Chikungunya) ELISA | Diesse | IgG ELISA | NA |
| Anti CHIKV IFFT | EUROIMMUN | IFFT | (1) |
| Anti-CHIKV ELISA (IgG) | IgG ELISA | (2) |
| Chikungunya Virus IgG ELISA | GenWay | IgG ELISA | NA |
| Chikungunya IgG ELISA | IBL International | IgG ELISA | NA |
| CHIKjj *Detect*™IgG ELISA Kit | InBios | IgG ELISA | (2) |
| NovaLisa Chikungunya IgG µ-capture ELISA | Novatec | IgG ELISA | NA |

Supplementary data-Table 3. Commercially available tests for the detection of anti-CHIKV IgG antibodies.

1. Litzba N, Schuffenecker I, Zeller H, Drosten C, Emmerich P, Charrel R, et al. Evaluation of the first commercial chikungunya virus indirect immunofluorescence test. Journal of Virological Methods. 2008;149(1):175–179.

2. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparc-Goffart I. Evaluation of Commercially Available Serologic Diagnostic Tests for Chikungunya Virus. Emerg Infect Dis. 2014 Dec;20(12):2129–32.